Zacks Investment Research on MSN
Moderna (MRNA) may report negative earnings: Know the trend ahead of next week's release
The market expects Moderna (MRNA) to deliver a year-over-year increase in earnings on higher revenues when it reports results ...
In vitro transcribed mRNA has lived up to its potential as a game-changing disruptive vaccine modality during the COVID-19 ...
Cartesian Therapeutics' lead asset, Descartes-08, demonstrated a 7.1-point MG-ADL reduction at 12 months in Phase 2b. Find ...
The Department of Health and Human Services (HHS) is winding down its mRNA vaccine development activities under the Biomedical Advanced Research and Development Authority (BARDA), the agency announced ...
As BioNTech works to establish a production footprint for mRNA vaccines in Africa, two EU groups have offered financial backing to the company's efforts. The European Commission pledged a 35 million ...
The Trump administration on Tuesday eliminated 22 mRNA vaccine development projects for COVID-19 and bird flu, a stark shift away from technology credited with bringing the United States out of the ...
The mRNA-based Covid vaccines helped blunt the impact of the pandemic but also sparked political backlash that has threatened ...
A landmark Phase 3 trial has begun in the UK and US to test Moderna’s mRNA-1018 vaccine against the H5N1 bird flu strain, a virus with pandemic potential. The study will assess safety and immune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results